NCT07580092已完成不适用
Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6,967
- 试验地点
- 1
研究概览
简要总结
The aim of this study is to compare the construct validity (convergent validity and known-groups validity) and responsiveness of EQ-5D-3L and EQ-5D-5L in patients with inflammatory joint disease. The study is based on prospectively collected data through the Swedish Rheumatology Quality Register (SRQ).
详细描述
A detailed description of the study can be found in the uploaded document titled 'Study Protocol and Statistical Analysis Plan.'
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Agreed to participate in the study
- •≥18 years at the time of the first measurement
- •A diagnosis of rheumatoid arthritis (RA), polyarthritis, psoriatic arthritis (PsA), or ankylosing spondylitis (AS)
- •Complete registration of responses in the EQ-5D-3L and EQ-5D-5L descriptive system at least at one time point (one visit)
- •For patients with RA: At least one measurement with Disease Activity Score 28 (DAS28) reported in relation to the same visit as the EQ-5D was registered
- •For patients with polyarthritis: At least one measurement with DAS28 reported in relation to the same visit as the EQ-5D was registered
- •For patients with PsA: At least one measurement with DAS28 or Disease Activity in Psoriatic Arthritis (DAPSA) reported in relation to the same visit as the EQ-5D was registered
- •For patients with AS: At least one measurement with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) or the Axial Spondyloarthritis Disease Activity Score (ASDAS) reported in relation to the same visit as the EQ-5D was registered
排除标准
- 未提供
研究者
Emelie Heintz
Associate professor
Karolinska Institutet
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
单中心、双盲、安慰剂对照、剂量递增的 Ia 期临床研究评估 EA5 在成人健康受试者中单次给药的安全性、耐受性及药代 / 药效学特征ChiCTR2300072738苏州铂维生物科技有限公司
Unknown
3 期
一项评价 QX005N 在中国中度至重度特应性皮炎受试者中的有效性和安全性的随机、双盲、多中心、安慰剂对照的 III 期临床研究ChiCTR2400082722江苏荃信生物医药股份有限公司
进行中（未招募）
3 期
QX005N 注射液特应性皮炎 III 期临床试验中重度特应性皮炎CTR20241068江苏荃信生物医药有限公司 / 江苏荃信生物医药股份有限公司
进行中（未招募）
3 期
QX005N 注射液特应性皮炎 III 期临床试验中重度特应性皮炎CTR20241068江苏荃信生物医药有限公司 / 江苏荃信生物医药股份有限公司
Unknown
1 期
评价雾化经口吸入 LQ036 在中国健康受试者体内的耐受性、安全性、免疫原性和药代动力学的单中心、随机、双盲、 安慰剂对照的 Ia 期临床研究ChiCTR2200063120上海洛启生物医药技术有限公司64